Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
bispecific antibodies
Fierce Pharma
Akeso CEO touts biliary tract win, counters ivonescimab debate
The Akeso CEO also pushed back against new debates around dataset fluctuations in NSCLC.
Angus Liu
Aug 26, 2026 11:11am
AstraZeneca ends phase 3 cancer trial as bispecific underwhelms
Aug 17, 2026 4:45am
Context ends bispecific trial to extend runway deeper into 2027
Aug 6, 2026 5:55am
Merck briefly posts trial plan for PD-1xVEGF and TROP2 ADC combo
Jul 29, 2026 3:00pm
Caldera hits Nasdaq via Synlogic reverse merger
Jul 29, 2026 8:56am
Ollin hauls in $330M for Vabysmo challenger's ph. 3 gauntlet
Jun 24, 2026 7:00am
